Three years ago, at a fundraiser near Philadelphia for theCuring Retinal Blindness Foundation, I stood, dumbstruck, as young teen Christian Guardino took the stage and belted outDont Stop Believing. Christian had recently undergone gene therapy that was already beginning to illuminate his darkening world but most in the crowd didnt know that.
Next to me was Dr. Jean Bennett, the physician-scientist who pioneered the gene therapy for what was then called Leber congenital amaurosis type 2. She asked me not to tell anyone about Christians treatment.
The world heard Christian last month when he performed in June on forAmericans Got Talent, singing the Jackson 5s Whos Lovin You.Fox Newsmentioned his blindness in what is perhaps the greatest oversimplification of a biotechnology of all time:When Christian Guardino was young, he learned that he would lose his sight. Fortunately, thanks to some gene therapy, he later regained the gift of sight. In the interim, he turned to music and stuck with it.
A Long Time Coming
Christian didnt just order up gene therapy like a side of fries.
The first clinical trial of gene therapy for a single-gene disease in the U.S. was in 1990. The publication of the phase 3 clinical trial data for the gene therapy for RPE65-mediated inherited retinal dystrophy, the disease that Christian has, bestows the name Luxturna, and FDA acceptance ofSpark TherapeuticsBiologics License Application (BLA) with priority review. These are giant steps forward in achieving the companys mission statement to challenge the inevitability of genetic disease.
Corey Haas owes his vision to the gene therapy he received at age 8.
Corey Haas owes his vision to the gene therapy he received at age 8. He is 14 in the accompanying photo, and will turn 17 in September.
The decade-long story of the clinical trial for the inherited blindness frames my history of gene therapy, published in 2012.The Forever Fix: Gene Therapy and the Boy Who Saved It(St. Martins Press, 2012) follows Corey Haas, the same age as Christian, who had his first eye treated in 2008 and sees so well that he goes fishing and turkey hunting. Without gene therapy, his world would be dark. Since the book came out Ive followed families whose children are having gene therapy for a variety of conditions right here atDNA Science.
The phase 3 findings for the blindness, published inThe Lancet, evaluate 21 patients in the treatment group and 10 others randomized to the control group who continued to have their vision evaluated the same way that the treated patients did (because sham surgery isnt ethical). A year later, all of the controls had the procedure too. And all have done great as have others in the earlier clinical trials.
The crux of the research, and part of what took so long, was the invention of a mobility course to evaluate a persons ability to navigate obstacles on a winding pathway under low light conditions. A test of real life, its a crucial complement to standard assessments of visual field, visual acuity, and imaging the layers of the retina.
Ill never forget watching Corey at his two-year check-up at Childrens Hospital of Philadelphia (CHOP) tackle the mobility course after just one eye had been treated. Covering that eye, the boy wobbled and careened, Dr. Jean offering her hand when he teetered too far of course. Yet covering his still-blind eye, he zipped through the maze.
Q&A withDr. Katherine High
The media largely ignored the blindness gene therapy news last week, perhaps because a few days earlier came news of an FDA advisory committees thumbs up for chimeric antigen receptor (CAR) technology to treat a form of leukemia. Two genetics news stories in one week? Nah.
I was frustrated. CAR, although widely described asgene therapybecause it sticks DNA into viruses, isnt really. Instead, it creates a double-whammy drone-like not-seen-in-nature immune response; it doesnt bolster a deficient enzyme. And a cancer is not at all like a single-gene disease.
So I believe that Luxturna to treatRPE65blindness will still be the first actual gene therapy approval.Katherine High, MD, president, chief scientific officer and a founder ofSpark Therapeutics, agrees. I spoke with her earlier this week about the recent progress. An excellent interview about her background ishere.
Ricki Lewis:How will patients be selected to receive Luxturna? Is newborn screening plausible?
Katherine High:Its for symptoms of vision loss in people with two autosomal recessive mutations in the geneRPE65. Initial licensing will be for children 3 years of age through adults. All of our work was done in children aged 3 or older, because treating younger children would require innovations in surgical technique.
RL:Can you describe the protocol?
KH:The first eye is done and within 6 to 18 days, the second eye is done. So it takes about 2 weeks. The protocol provides a chance to make sure the first eye is healing and that the person has the opportunity to get the patch off.
RL:What will Luxturna cost? Will savings on no-longer-needed treatments and aids be considered?
KH:Cost is under discussion. Part of the organization that Spark is building is to make sure that anybody who is a candidate for the therapy will have access to it. Were talking to key stakeholders the patient community, payers, health care providers, and policy makers. Its different in Europe, where all social services and educational services and so forth required for people with impaired vision comes out of the same pot, whereas in the US those kinds of services are separate from the payers. So cost, and cost savings, will involve a more complicated algorithm.
RL:Spark is also developing gene therapy forhemophilia B, with interim findings recently presented at the International Society for Thrombosis and Hemostasis meeting in Berlin. Youve been working on that condition a long time! Update?
KH: Its hard to imagine what its like to take clotting factor once or twice a week for your whole life and then not to have to. Individuals with hemophilia are always planning around when they last had an infusion of factor IX. Do the infusion, the level of clotting factor peaks, and then it slowly comes down until the next infusion. As its coming down, the patient is at risk for bleeds. So people always have to think about it.Id like to go to the gym, and the last infusion was 40 hours ago. Can I? I want to take the kids down to the park. When was my last infusion?
RL:Another hemophilia B clinical trial uses the oldest form of genome editing,zinc finger nucleases. Are the two approaches in competition? (Gene therapy adds a gene; gene editing can swap a functioning gene for a mutant one.)
KH:They both could work. Clinical experience with gene editing is much earlier and it can take time in clinical development to uncover challenges and work through them. With these complex biologics, only a certain amount can be learned from the animal models. Then in clinical investigation you have to look at results and understand what they mean and possibly modify a protocol or institute a course correction. That was true for monoclonal antibodies, for bone marrow transplants, and for straight gene therapy. Will gene editing have a shorter path? Perhaps.
RL:Where will gene therapy be in five years?
KH:Clinical development timelines will become shorter. We started the clinical work for voretigene (aka Luxturna) in 2007, but I began working on it, with Jean Bennett and Al Maguire, in 2005. We initiated the trial in 2007. We paused along the way to discuss with regulators the best way to proceed. We had to do a natural history study, for example, and we had to evaluate the mobility test. We had to build the infrastructure for studying this ultrarare form of inherited retinal dystrophy.
We will continue to see proof-of-concept of gene therapy demonstrated in different target tissues. Were seeing promising results in gene delivery to the liver and the central nervous system. I hope we will see continued accumulation of successful clinical results in a range of target tissues and continued progress in bringing gene therapy products to licensing. One of the challenges in my career has been interesting physicians in learning more about gene therapy. When gene therapy products are licensed, there will be increased interest in the medical community, and that will help to expand opportunities.
RL:Your attempt to catalyze interest in gene transfer goes back pretty far, as does gene therapy itself. And of course the field had to overcome the setbacks of the turn of the century Jesse Gelsingers death and the boys who developed leukemia.
KH:Back in the 1990s when I worked with a gene therapy company in northern California, I kept telling them they should work on this gene,RPE65. They declined because of the small patient population, and I said its a great proof-of-concept idea and its probably going to work. (Its a straightforward enzyme replacement via genetic instructions to an accessible tissue.)
After the high profile adverse events and everyone pulling out of gene therapy, Childrens Hospital of Philadelphia gave us the resources to set up vector production in-house. Dr. Steven Altschuler, then CHOP CEO and now chairman of the board at Spark, said well help, but you cant just commit the resources all to hemophilia. You have to work on a genetic disease that affects children. I said I know exactly what Im going to do, and I went and talked to Jean Bennett.
CHOP gave us the luxury of working without worrying how big the market was. I will always be grateful to Dr. Altschuler for having had the courage to make that decision when things didnt look very good for gene therapy. The other important decision he made was to spin out Spark. We were discussing many possibilities, including partnering with biotech or pharma, but most of them knew very little about gene therapy. And I was concerned about what would happen to the program for gene therapy for this ultrarare disease if put in the hands of a big company and they have a bad year.
(Spark Therapeutics formed in March 2013, the month my book came out in paperback.)
RL:So when will ophthalmologists be able to save young people like Corey Haas and Christian Guardino from living in darkness?
KH:FDA has accepted the Biologics License Application for priority review. That means that they have 6 months to decide. So there will be much back and forth with requests for additional information, and then typically for a novel therapy like this they would arrange an advisory committee meeting.
RL:So 2018 will likely be the year for Luxturna to challenge the inevitability of this one genetic disease. Its a giant first step to achieving Sparks vision:A world where no life is limited by genetic disease.
A version of this article was originally published on the PLOSwebsite as Luxturna: A Giant Step Forward For Blindness Gene Therapy A Conversation with Dr. Kathy High and has been republished here with permission.
Ricki Lewis has a PhD in genetics and is a genetics counselor, science writer and author of Human Genetics: The Basics. Follow her at her website or Twitter @rickilewis.
Read more:
- About the Gene Therapy Review - November 8th, 2009 [November 8th, 2009]
- Contribute an Article - November 8th, 2009 [November 8th, 2009]
- EBSCO Publishing Deal - November 8th, 2009 [November 8th, 2009]
- Advertising Opportunities - November 8th, 2009 [November 8th, 2009]
- Instructions for Authors - November 8th, 2009 [November 8th, 2009]
- Isis Collaboration With Ortho-McNeil Inc for Metabolic Diseases - November 8th, 2009 [November 8th, 2009]
- Dystrophin Gene Transfer safe in Duchenne muscular dystrophy - November 8th, 2009 [November 8th, 2009]
- Researchers Identify Gene for Rare Form of Spinal Muscular Atrophy - November 8th, 2009 [November 8th, 2009]
- Fatal brain cancer tamed by New gene therapy - November 8th, 2009 [November 8th, 2009]
- Gene therapy effective in fighting obesity in mice - November 8th, 2009 [November 8th, 2009]
- Genzyme gene therapy for people with peripheral artery disease failed in a clinical trial to help them regain some mobility - November 8th, 2009 [November 8th, 2009]
- Gene Therapy May Stall Inherited Emphysema - December 31st, 2009 [December 31st, 2009]
- Gene Therapy and Stem Cells Save Limb - December 31st, 2009 [December 31st, 2009]
- TNVitamins.com – $10 Off Of $50 order - May 7th, 2011 [May 7th, 2011]
- 15% Off Any PetAlive Order - May 7th, 2011 [May 7th, 2011]
- At PetAlive – $10 off order of $50 or more - May 7th, 2011 [May 7th, 2011]
- Native Remedies coupon – 5% Off Any Order - May 7th, 2011 [May 7th, 2011]
- Native Remedies – Save $5 coupon - May 7th, 2011 [May 7th, 2011]
- Welcome to the Gene Therapy Review - May 15th, 2011 [May 15th, 2011]
- Editorial Board - May 15th, 2011 [May 15th, 2011]
- Gene Therapy Job Board - May 15th, 2011 [May 15th, 2011]
- Corporate Membership - May 22nd, 2011 [May 22nd, 2011]
- Native Remedies coupon – 25% Off Any Order - May 29th, 2011 [May 29th, 2011]
- What is Gene Therapy? - June 19th, 2011 [June 19th, 2011]
- Research and Markets: Recent Advances in Cancer Research and Therapy - Increased Research on one of the Major Causes ... - April 25th, 2012 [April 25th, 2012]
- Gene Therapy part 2 - Video - April 30th, 2012 [April 30th, 2012]
- Gene therapy reverses Parkinson's symptoms: study - Video - April 30th, 2012 [April 30th, 2012]
- CBS This Morning - Gene therapy reverses Parkinson's symptoms: study - Video - April 30th, 2012 [April 30th, 2012]
- Engineering adenoviruses for gene therapy - Video - April 30th, 2012 [April 30th, 2012]
- What is Gene Therapy (The General Explains) - Video - April 30th, 2012 [April 30th, 2012]
- What is Gene Therapy - Animation - Video - April 30th, 2012 [April 30th, 2012]
- Microbiology Gene Therapy - Video - April 30th, 2012 [April 30th, 2012]
- Gene Therapy in Detail - Video - April 30th, 2012 [April 30th, 2012]
- Breakthrough in Haemophilia treatment - Video - April 30th, 2012 [April 30th, 2012]
- Virology Seminar - Gene Therapy - April 30th, 2012 [April 30th, 2012]
- Gene Therapy Video - Video - April 30th, 2012 [April 30th, 2012]
- Study: Gene Therapy for HIV Safe, But Effectiveness Still Unclear - May 4th, 2012 [May 4th, 2012]
- Gene Therapy Safe in Decade-Long HIV Study That May Widen Use - May 4th, 2012 [May 4th, 2012]
- Gene therapy for HIV safe, but effectiveness still unclear - May 4th, 2012 [May 4th, 2012]
- A Step Forward For Gene Therapy To Treat HIV - May 4th, 2012 [May 4th, 2012]
- A Media Event on Clinical Developments in Gene and Cell Therapy - May 4th, 2012 [May 4th, 2012]
- Families of SMA Awards New Funding to Advance a CNS Delivered Gene Therapy for Spinal Muscular Atrophy - May 4th, 2012 [May 4th, 2012]
- AIDS gene therapy safe -- is it a "cure"? - May 4th, 2012 [May 4th, 2012]
- Generational Achievements in Gene and Cell Therapy Honored at ASGCT 15th Annual Meeting - May 5th, 2012 [May 5th, 2012]
- Lewis speaks on gene therapy at Lexington Community Education event - May 7th, 2012 [May 7th, 2012]
- Penn researchers report a gene-therapy success - May 10th, 2012 [May 10th, 2012]
- Gene therapy for hearing loss: Potential and limitations - May 13th, 2012 [May 13th, 2012]
- Gene therapy extends mouse lifespan by 24 pc - May 16th, 2012 [May 16th, 2012]
- Gene therapy dramatically extends mouse lifespan - May 16th, 2012 [May 16th, 2012]
- Gene therapy may extend life: Study - May 16th, 2012 [May 16th, 2012]
- First gene therapy successful against aging-associated decline: Mouse lifespan extended up to 24% with a single ... - May 16th, 2012 [May 16th, 2012]
- Gene Therapy Extends Mouse Lifespan - May 16th, 2012 [May 16th, 2012]
- Gene Therapy for Brain Disease - May 17th, 2012 [May 17th, 2012]
- Children with rare, incurable brain disease improve after gene therapy - May 17th, 2012 [May 17th, 2012]
- FIRST Anti-Aging Gene Therapy (Brainstorm Ep72) - Video - May 23rd, 2012 [May 23rd, 2012]
- Gene therapy can correct forms of severe combined immunodeficiency - May 25th, 2012 [May 25th, 2012]
- RetroSense Therapeutics Completes pre-IND Meeting for RST-001 - May 25th, 2012 [May 25th, 2012]
- Gene therapy can correct forms of severe combined immunodeficiency, study suggests - May 26th, 2012 [May 26th, 2012]
- Alliance for Cancer Gene Therapy celebrates 10 years - May 29th, 2012 [May 29th, 2012]
- Research on gene therapy by Prasad Eye - June 1st, 2012 [June 1st, 2012]
- Baxter Announces Collaboration with Chatham Therapeutics for Factor IX Hemophilia B Gene Therapy Treatment - June 5th, 2012 [June 5th, 2012]
- Transgenomic Launches Breakthrough Blood-Based Cancer Gene Testing Technology at 2012 ASCO Annual Meeting - June 5th, 2012 [June 5th, 2012]
- Baxter Inks Deal with Chatham - June 6th, 2012 [June 6th, 2012]
- PIK3CA Gene Patent for Predicting Response to Targeted Therapy Issued – Exclusively Licensed to Transgenomic - June 11th, 2012 [June 11th, 2012]
- SalutarisMD Announces Positive Case Report of a New Investigational Wet AMD Therapy at ARVO - June 15th, 2012 [June 15th, 2012]
- Research and Markets: Gene Therapy - Global Strategic Business Report - 2012 - June 15th, 2012 [June 15th, 2012]
- New York Law Firm’s MesotheliomaHelp.net Site Publishes Interview with Gene Therapy Author - June 17th, 2012 [June 17th, 2012]
- uniQure Extends Collaboration with Protein Sciences Corporation on Use of its expresSF+® Cell Line for Gene Therapy - June 19th, 2012 [June 19th, 2012]
- Anti-cocaine vaccine described in Human Gene Therapy Journal - June 19th, 2012 [June 19th, 2012]
- bluebird bio Receives U.S. and European Orphan Drug Designation for Novel Gene Therapy to Treat Adrenoleukodystrophy - June 19th, 2012 [June 19th, 2012]
- Close to a cure: Greater Hartford takes on rare Jewish genetic disease - June 19th, 2012 [June 19th, 2012]
- Gene Therapy Helps Treat Children with Rare Brain Disorder - June 20th, 2012 [June 20th, 2012]
- Gold nanoparticles capable of 'unzipping' DNA - June 21st, 2012 [June 21st, 2012]
- ‘Gene-silencing’ drug can halt and reverse deadly brain disorder - June 21st, 2012 [June 21st, 2012]
- uniQure Collaborates with UCSF on GDNF Gene Therapy in Parkinson's Disease - June 22nd, 2012 [June 22nd, 2012]
- Gene-silencing method offers possible therapy for Huntington's disease - June 22nd, 2012 [June 22nd, 2012]
- Gene mutations cause massive brain asymmetry - June 24th, 2012 [June 24th, 2012]
- Research and Markets: Translational Regenerative Medicine - Oncology, CNS and Cardiovascular-Rich Pipeline Features ... - June 25th, 2012 [June 25th, 2012]
- Stress Blocks Gene That Guards Brain Against Depression - June 26th, 2012 [June 26th, 2012]
- Targeted gene therapy enhances treatment for Pompe disease - June 26th, 2012 [June 26th, 2012]